Payment overview · 2025
General Payments
$365.44
19 reported records · 9 companies
Healthcare provider profile · identity verified
Robyn Mann Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, GA · NPI 1013019363
Verified facts
What the public records show
CMS Open Payments records show Robyn Mann Johnson, M.D. received $365.44 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 618 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.05 | 26.3% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $74.27 | 20.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.36 | 14.1% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $44.29 | 12.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $40.89 | 11.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.12 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.28 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.60 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.58 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.44 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $57.61 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.00 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $40.89 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 618 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
40 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
618 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 38 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 994 | 304 |
| Amlodipine Besylate | Amlodipine Besylate | 709 | 222 |
| Ozempic | Semaglutide | 618 | 86 |
| Losartan Potassium | Losartan Potassium | 611 | 182 |
| Gabapentin | Gabapentin | 593 | 172 |
| Famotidine | Famotidine | 575 | 144 |
| Potassium Chloride | Potassium Chloride | 486 | 138 |
| Hydrochlorothiazide | Hydrochlorothiazide | 422 | 129 |
| Fluticasone Propionate | Fluticasone Propionate | 398 | 151 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 393 | 121 |
| Omeprazole | Omeprazole | 362 | 103 |
| Furosemide | Furosemide | 330 | 100 |
| Nifedipine Er | Nifedipine | 301 | 89 |
| Lisinopril | Lisinopril | 268 | 77 |
| Hydralazine Hcl | Hydralazine Hcl | 238 | 72 |
| Atenolol | Atenolol | 236 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 229 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 57 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 219 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 55 |
| Metformin Hcl | Metformin Hcl | 207 | 60 |
| Doxazosin Mesylate | Doxazosin Mesylate | 200 | 59 |
| Tramadol Hcl | Tramadol Hcl | 193 | 44 |
| Simvastatin | Simvastatin | 192 | 52 |
| Januvia | Sitagliptin Phosphate | 188 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 57 |
| Carvedilol | Carvedilol | 182 | 58 |
| Azelastine Hcl | Azelastine Hcl | 180 | 92 |
| Allopurinol | Allopurinol | 167 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 43 |
| Mirtazapine | Mirtazapine | 145 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 144 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 47 |
| Montelukast Sodium | Montelukast Sodium | 134 | 35 |
| Sertraline Hcl | Sertraline Hcl | 128 | 45 |
| Glipizide | Glipizide | 123 | 38 |
| Eliquis | Apixaban | 122 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 28 |
| Alendronate Sodium | Alendronate Sodium | 104 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 22 |
| Spironolactone | Spironolactone | 95 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 25 |
| Pregabalin | Pregabalin | 82 | 19 |
| Lovastatin | Lovastatin | 78 | 23 |
| Jardiance | Empagliflozin | 75 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 41 |
| Symbicort | Budesonide/Formoterol Fumarate | 68 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 12 |
| Meclizine Hcl | Meclizine Hcl | 62 | 19 |
| Glimepiride | Glimepiride | 61 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 22 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 58 | 25 |
| Prednisone | Prednisone | 56 | 48 |
| Metformin Hcl Er | Metformin Hcl | 51 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 20 |
| Colchicine | Colchicine | 50 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Levetiracetam | Levetiracetam | 45 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 43 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 42 |
| Glipizide Er | Glipizide | 43 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 15 |
| Levemir Flexpen | Insulin Detemir | 41 | 12 |
| Valacyclovir | Valacyclovir Hcl | 41 | 14 |
| Valsartan | Valsartan | 41 | 12 |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 40 | 36 |
| Xarelto | Rivaroxaban | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 39 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 16 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 33 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Nystatin | Nystatin | 30 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Lactulose | Lactulose | 26 | 11 |
| Meloxicam | Meloxicam | 26 | 13 |
| Amoxicillin | Amoxicillin | 25 | 25 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Lidocaine | Lidocaine | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.44 · 19 records | Novo Nordisk Inc | ABRYSVO, CABENUVA, DOVATO, Dexcom G6 Transmitter, JOURNAVX, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error